Mekinist approved in Europe but commercial success uncertain
This article was originally published in Scrip
Executive Summary
Good news for GlaxoSmithKline and Novartis: the European Medicines Agency has approved Mekinist (trametinib) as a monotherapy for melanoma with a BRAF V600 mutation, following a positive CHMP recommendation earlier this year (scripintelligence.com, 25 April 2014). Mekinist is the first MEK inhibitor to be licensed in Europe.